Close Menu

NEW YORK, Oct. 25 – Pfizer licensed Valentis’ GeneSwitch gene regulation technology, the companies announced on Wednesday.

The license is non-exclusive for research-use only.

Financial details of the agreement were not disclosed.

Burlingame, Calif.-based Valentis’ GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, according to the company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.